TX-DAVE&BUSTRS/BSTRO-GRP
Dave & Buster's Entertainment, Inc., the ultimate destination for food, drink and entertainment is delighted to announce its latest franchise agreement furthering the brands development in APAC. Dave & Buster’s has finalized a deal to open five new stores in the Philippines, raising the international development store count to 38.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240416173901/en/
Antonio Bautista, Chief International Development Officer of Dave & Buster’s and Paul Manuud, President of The Bistro Group (Photo: Business Wire)
Antonio Bautista, Chief International Development Officer at Dave & Buster’s, stated "We are thrilled to announce our expansion into the Philippines, marking another significant milestone in our global growth strategy. Our partnership with The Bistro Group in the Philippines aligns with our mission to deliver exceptional 'Eat, Drink, Play, and Watch' experiences to a broader audience. The Bistro Group's reputation as a trendsetter in the F&B industry in Southeast Asia and beyond makes them an ideal partner for introducing our brand to the Filipino market."
Paul Manuud, President of The Bistro Group remarks, "We were impressed by Dave & Buster’s holistic offering in the hospitality industry where guests can eat, drink, play and watch sports shows all in one location. It is a very good concept that could pioneer well in the Philippines, being poised to be the first of its kind in the local F & B landscape,” expressing enthusiasm for the partnership, he continued, "Entering the 'eatertainment' sector with a renowned brand is an exciting development for us. This collaboration enhances our portfolio, enabling us to offer unparalleled dining and entertainment experiences in the Philippines."
Dave & Buster's has implemented several strategic initiatives to ensure a successful global expansion, including a customizable footprint tailored to meet specific market requirements and the localization of menu offerings with high regional resonance to cater to local preferences and tastes. They have also introduced a proprietary dynamic pricing model to offer flexible pricing options, launched global marketing programs that are demographically agnostic yet locally executable, and implemented a unique amusement strategy and packages to differentiate themselves in the market.
Dave & Buster's is also excited to offer localized entertainment and late-night programming for customers and introduce immersive experiences to enhance customer engagement in the competitive socializing space. With these initiatives, Dave & Buster's is confident they will provide an exceptional experience to their global customers.
About Dave & Buster’s
Founded in 1982 and headquartered in Coppell, Texas, Dave & Buster's Entertainment, Inc., is the owner and operator of 223 venues in North America that offer premier entertainment and dining experiences to guests through two distinct brands: Dave & Buster’s and Main Event. The Company has 164 Dave & Buster’s branded stores in 42 states, Puerto Rico, and Canada and offers guests the opportunity to "Eat Drink Play & Watch," all in one location. Each store offers a full menu of entrées and appetizers, a complete selection of alcoholic and non-alcoholic beverages, and an extensive assortment of entertainment attractions centered around playing games and watching live sports and other televised events. The Company also operates 59 Main Event branded stores in 20 states across the country, and offers state-of-the-art bowling, laser tag, hundreds of arcade games and virtual reality, making it the perfect place for families to connect and make memories. For more information, visit daveandbusters.com.
About The Bistro Group:
Founded in 1994, The Bistro Group is one of the Philippines’ most progressive restaurant chains that popularized the casual dining concept with the entry of TGIFridays in the country almost 30 years ago. Its success led to the launch of other world-class brands such as Italianni’s, Denny’s, Buffalo Wild Wings, Texas Roadhouse, Randy’s Donuts and Hard Rock Café among others as well as Asian concepts like Watami, Modern Shang, Bulgogi Brothers and Fish & Co. The company owns and operates Bistronomia, a collection of boutique Spanish/Mediterranean restaurants, Las Flores, Rambla, Tomatito, BCN by Las Flores and Rumba. Also part of its portfolio is TBG Elite by award-winning corporate executive chef, Josh Boutwood. Its premier restaurants, highlighted by quality ingredients, seasonality and unique cooking methods are Helm, The Test Kitchen, Savage and Ember. The Bistro Group is driven by a people-focused philosophy that is the backbone of its success. Passion and commitment propel its operations…in every restaurant, behind every dish and with every service rendered with generous hospitality.
For restaurant concepts and more information about The Bistro Group, visit https://www.bistro.com.ph/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240416173901/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
